WO2020032883A3 - Synergistic effects of a novel ketoprofen formulation including a gastro protective agent - Google Patents

Synergistic effects of a novel ketoprofen formulation including a gastro protective agent Download PDF

Info

Publication number
WO2020032883A3
WO2020032883A3 PCT/TR2019/050282 TR2019050282W WO2020032883A3 WO 2020032883 A3 WO2020032883 A3 WO 2020032883A3 TR 2019050282 W TR2019050282 W TR 2019050282W WO 2020032883 A3 WO2020032883 A3 WO 2020032883A3
Authority
WO
WIPO (PCT)
Prior art keywords
protective agent
novel
gastro
ketoprofen
synergistic effects
Prior art date
Application number
PCT/TR2019/050282
Other languages
French (fr)
Other versions
WO2020032883A2 (en
Inventor
Mehmet Nevzat PISAK
Original Assignee
Pisak Mehmet Nevzat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pisak Mehmet Nevzat filed Critical Pisak Mehmet Nevzat
Publication of WO2020032883A2 publication Critical patent/WO2020032883A2/en
Publication of WO2020032883A3 publication Critical patent/WO2020032883A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/10—Carbonates; Bicarbonates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to pharmaceutical combinations comprising ketoprofen or a pharmaceutically acceptable derivative thereof and an H2 receptor antagonist as gastro-protective agent, preferably famotidine, to oral dosage forms comprising such combinations and to processes for the preparation thereof. The present invention relates to an oral immediate release pharmaceutical composition in a single unit dosage form comprising ketoprofen or a pharmaceutically acceptable derivative thereof, a H2 receptor antagonist as a gastro protective agent, at least one carbonate and at least one non-ionic surfactant.
PCT/TR2019/050282 2018-04-26 2019-04-26 Synergistic effects of a novel ketoprofen formulation including a gastro protective agent WO2020032883A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR201805907 2018-04-26
TR2018/05907 2018-04-26

Publications (2)

Publication Number Publication Date
WO2020032883A2 WO2020032883A2 (en) 2020-02-13
WO2020032883A3 true WO2020032883A3 (en) 2020-03-26

Family

ID=69414317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2019/050282 WO2020032883A2 (en) 2018-04-26 2019-04-26 Synergistic effects of a novel ketoprofen formulation including a gastro protective agent

Country Status (1)

Country Link
WO (1) WO2020032883A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102552315B1 (en) * 2020-11-11 2023-07-06 대원제약주식회사 Pharmaceutical composition with reduced gastrointestinal disorder comprising novel salt of pelubiprofen as an active ingredient

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US20050249811A1 (en) * 2001-06-01 2005-11-10 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013280A (en) * 1997-10-07 2000-01-11 Fuisz Technologies Ltd. Immediate release dosage forms containing microspheres
US20050249811A1 (en) * 2001-06-01 2005-11-10 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DONTHI, M. R. ET AL.: "Preparation and Evaluation of Fixed Combination of Ketoprofen Enteric Coated and Famotidine Floating Mini Tablets by Single Unit Encapsulation System", JOURNAL OF BIOEQUIVALENCE & BIOAVAILABILITY, vol. 7, no. 6, 22 October 2015 (2015-10-22), pages 279, XP055694890 *

Also Published As

Publication number Publication date
WO2020032883A2 (en) 2020-02-13

Similar Documents

Publication Publication Date Title
WO2015120110A3 (en) Novel pharmaceutical formulations
HRP20150644T1 (en) Method of treating atrial fibrillation
MX2010003923A (en) Pharmaceutical formulation of valsartan.
WO2018165404A8 (en) Pharmaceutical formulations of phloroglucinol and trimethylphloroglucinol
WO2007103200A3 (en) Oral controlled release formulation for sedative and hypnotic agents
EA202090984A1 (en) ORAL DISPERSED DOSAGE UNIT CONTAINING THE ESTETROL COMPONENT
NZ600231A (en) Pharmaceutical compositions comprising sigma receptor ligands
UA116334C2 (en) SOLID FORMS OF BENDAMUSTINE DOSAGE
WO2008142572A3 (en) Controlled release tablet formulation containing magnesium aluminometasilicate
BR112012009857A2 (en) solid pharmaceutical compositions containing an integrase inhibitor
UA102120C2 (en) Oral dosage forms of bendamustine
CO6150126A2 (en) FORMULATIONS OF IMMEDIATE RELEASE TABLETS FROM A TROMBINE RECEIVER ANTAGONIST
PH12019500154A1 (en) Formulation having improved ph-dependent drug-release characteristics, containing esomeprazole or pharmaceutically acceptable salt thereof
WO2019194773A3 (en) The combination comprising linagliptin and metformin
MY173873A (en) Oral dosage forms of bendamustine
WO2012020301A3 (en) Oral controlled release pharmaceutical compositions of blonanserin
WO2020032883A3 (en) Synergistic effects of a novel ketoprofen formulation including a gastro protective agent
HRP20201436T1 (en) Macrogols for application to the mucosa, and therapeutic uses thereof
WO2020013776A3 (en) Synergistic effect of naproxen and a gastro protective agent for the treatment of pain and inflammation
WO2018069805A3 (en) Method for preparation of liquid oral composition of l-thyroxin
WO2017152130A8 (en) Pharmaceutical compositions
WO2019203759A3 (en) Combinations of etodolac with h2 receptor antagonists for the treatment of pain and inflammation.
WO2020013781A3 (en) Synergistic effect of flurbiprofen and a gastro protective agent for the treatment of pain and inflammation
WO2020018048A3 (en) An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate
WO2016091805A3 (en) Naloxone monopreparation and multi-layer tablet

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19848208

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01.02.2021)

122 Ep: pct application non-entry in european phase

Ref document number: 19848208

Country of ref document: EP

Kind code of ref document: A2